Coherus Inks $300m Credit Agreement With Ranibizumab Approval Worth $50m
US Biotech Also Reveals Latest Progress With On-Body Pegfilgrastim Injector
Presenting at the 40th Annual J.P. Morgan Health Care Conference, Coherus BioSciences provided the latest on the firm’s highly-anticipated proposed on-body injector device for pegfilgrastim, days after securing a $300m credit agreement that includes $50m related to the firm’s proposed ranibizumab biosimilar.
